Reaching Impact, Saturation and Epidemic Control (RISE)

POST- TRAINING ASSESSMENT FORM

PARTICIPANT HANDOUT-7.2.1

Tick (✓) the correct option.

- 1. What should be the purity of medical oxygen administered to COVID-19 patients?
 - a) 80%
 - b) 85%
 - c) 90%
 - d) 96%
- 2. Which of the following is not an objective of oxygen therapy?
 - a) Correct lung fibrosis
 - b) Correct documented or suspected hypoxemia
 - c) Decrease the symptoms associated with chronic hypoxemia
 - d) Decrease the workload hypoxemia imposes on the cardiopulmonary system
- 3. Oxygen therapy is needed to cater the needs at which level of healthcare system
 - a) Primary
 - b) Secondary
 - c) Tertiary
 - d) All the above
- 4. Which of the following is not the source of medical oxygen?
 - a) Oxygen concentrator
 - b) Ventilator
 - c) Oxygen cylinder
 - d) PSA/VSA/VPSA Plant
 - e) Liquid medical oxygen (ASU plant)
- 5. Liquid oxygen is less concentrated and hence can only be stored in larger tank to ensure continuous supply at high pressure.
 - a) True
 - b) False
- 6. Which of the following is a high flow oxygen device?
 - a) Nasal catheter
 - b) Non-rebreathing mask
 - c) Venturi mask
 - d) Oxygen tent





- 7. Choose the correct color code for oxygen gas cylinder
 - a) Yellow
 - b) Black
 - c) White
 - d) Red
- 8. Use of humidifier will not be recommended when
 - a) Cold oxygen is delivered
 - b) Delivering oxygen at higher than standard flow rates
 - c) Methods of oxygen bypass the nose
 - d) Delivering oxygen at relatively low flow rates
- 9. Which of the following solutions should not be used for decontamination of oxygen therapy devices?
 - a) Peracetic acid
 - b) Sodium hypochlorite
 - c) Stabilized hydrogen peroxide
 - d) Acetone
- 10. Which of the following factors are responsible for oxygen wastage?
 - a) Faulty valves
 - b) Washer not properly placed
 - c) Improper maintenance of dura cylinder
 - d) Using high flow nasal oxygen
 - e) All of the above

Disclaimer: This document was made possible with support from the United States Agency for International Development funded RISE program, under the terms of the cooperative agreement 7200AA19CA00003. The contents are the responsibility of the RISE program and do not necessarily reflect the views of USAID or the United States Government.



